新浪登录
腾讯登录Stem Cells Trans Med：利用干细胞促进红细胞产生
| 导读 | 根据一项新的研究，利用人干细胞，研究人员开发出一种促进红细胞产生的新方法。他们的发现能够显著性地增加输血时所需的血液供应，而且他们的方法也能够被用来生产任何血型的血液。
美国纽约市阿尔伯特爱因斯坦医学院研究员Eric Bouhassira说，“我们将不同的细胞增殖技术综合在一起，从而能够10到100倍地增加红细胞产生的数量。”
<!--more-->
当前，用于拯救生... |
根据一项新的研究，利用人干细胞，研究人员开发出一种促进红细胞产生的新方法。他们的发现能够显著性地增加输血时所需的血液供应，而且他们的方法也能够被用来生产任何血型的血液。
美国纽约市阿尔伯特爱因斯坦医学院研究员Eric Bouhassira说，“我们将不同的细胞增殖技术综合在一起，从而能够10到100倍地增加红细胞产生的数量。”
<!--more-->
当前，用于拯救生命的输血所需的血液只能通过捐血来获得。因此，血液能够出现短缺，特别是那些罕见血型的血液。研究人员利用来自脐带血和循环血液中的干细胞和胚胎干细胞来更加高效地产生红细胞。
Bouhassira说，“科学家们规模化工业生长大量红细胞的能力可能在输血医学域领引发一场变革。通过基于捐血的系统的血液收集虽然能够很好地为我们服用，但是它的成本较高，容易遭受破坏，而且不足以满足一些需要进行输血的人们的需求。(这项研究中开发出的)方法可能是一个不错的长期替代选择。”
2012年8月2日，相关研究结果在线发表在<em>Stem Cells Translational Medicine</em>期刊上。
本文编译自<a href="http://medicalxpress.com/news/2012-08-stem-cells-boost-red-blood.html" target="_blank">Study uses stem cells to boost red blood cell production</a>
<div id="ztload">
<div> </div>
<div>
<div>
<img src="http://www.bioon.com/biology/UploadFiles/201208/2012080821173809.gif" alt="" width="113" height="149" border="0" />
<a title="" href="http://dx.doi.org/10.5966/sctm.2012-0059" target="_blank">doi: 10.5966/sctm.2012-0059</a>
PMC:
PMID:
</div>
<div>
<br/><strong>Novel, High-Yield Red Blood Cell Production Methods from CD34-Positive Cells Derived from Human Embryonic Stem, Yolk Sac, Fetal Liver, Cord Blood, and Peripheral Blood</strong><br/>
Emmanuel Olivier, Caihong Qiu and Eric E. Bouhassira
The current supply of red blood cells expressing rare blood groups is not sufficient to cover all the existing transfusion needs for chronically transfused patients, such as sickle cell disease homozygous carriers, because of alloimmunization. In vitro production of cultured red blood cells is slowly emerging as a possible complement to the existing collection-based red blood cell procurement system. The yield of cultured red blood cells can theoretically be maximized by amplifying the stem, progenitor, or precursor compartment. Here, we combined methods designed to expand these three compartments to optimize the yield of cultured red blood cells and found that exposing CD34+ cells to a short pulse of cytokines favorable for erythroid differentiation prior to stem cell expansion followed by progenitor expansion produced the highest yield of erythroid cells. This novel serum-free red blood cell production protocol was efficient on CD34+ cells derived from human embryonic stem cells, 6–8-week yolk sacs, 16–18-week fetal livers, cord blood, and peripheral blood. The yields of cells obtained with these new protocols were larger by an order of magnitude than the yields observed previously. Globin expression analysis by high-performance liquid chromatography revealed that these expansion protocols generally yielded red blood cells that expressed a globin profile similar to that expected for the developmental age of the CD34+ cells.
<br/>来源：生物谷
</div>
</div>
</div>
美国纽约市阿尔伯特爱因斯坦医学院研究员Eric Bouhassira说，“我们将不同的细胞增殖技术综合在一起，从而能够10到100倍地增加红细胞产生的数量。”
<!--more-->
当前，用于拯救生命的输血所需的血液只能通过捐血来获得。因此，血液能够出现短缺，特别是那些罕见血型的血液。研究人员利用来自脐带血和循环血液中的干细胞和胚胎干细胞来更加高效地产生红细胞。
Bouhassira说，“科学家们规模化工业生长大量红细胞的能力可能在输血医学域领引发一场变革。通过基于捐血的系统的血液收集虽然能够很好地为我们服用，但是它的成本较高，容易遭受破坏，而且不足以满足一些需要进行输血的人们的需求。(这项研究中开发出的)方法可能是一个不错的长期替代选择。”
2012年8月2日，相关研究结果在线发表在<em>Stem Cells Translational Medicine</em>期刊上。
本文编译自<a href="http://medicalxpress.com/news/2012-08-stem-cells-boost-red-blood.html" target="_blank">Study uses stem cells to boost red blood cell production</a>
<div id="ztload">
<div> </div>
<div>
<div>
<img src="http://www.bioon.com/biology/UploadFiles/201208/2012080821173809.gif" alt="" width="113" height="149" border="0" />
<a title="" href="http://dx.doi.org/10.5966/sctm.2012-0059" target="_blank">doi: 10.5966/sctm.2012-0059</a>
PMC:
PMID:
</div>
<div>
<br/><strong>Novel, High-Yield Red Blood Cell Production Methods from CD34-Positive Cells Derived from Human Embryonic Stem, Yolk Sac, Fetal Liver, Cord Blood, and Peripheral Blood</strong><br/>
Emmanuel Olivier, Caihong Qiu and Eric E. Bouhassira
The current supply of red blood cells expressing rare blood groups is not sufficient to cover all the existing transfusion needs for chronically transfused patients, such as sickle cell disease homozygous carriers, because of alloimmunization. In vitro production of cultured red blood cells is slowly emerging as a possible complement to the existing collection-based red blood cell procurement system. The yield of cultured red blood cells can theoretically be maximized by amplifying the stem, progenitor, or precursor compartment. Here, we combined methods designed to expand these three compartments to optimize the yield of cultured red blood cells and found that exposing CD34+ cells to a short pulse of cytokines favorable for erythroid differentiation prior to stem cell expansion followed by progenitor expansion produced the highest yield of erythroid cells. This novel serum-free red blood cell production protocol was efficient on CD34+ cells derived from human embryonic stem cells, 6–8-week yolk sacs, 16–18-week fetal livers, cord blood, and peripheral blood. The yields of cells obtained with these new protocols were larger by an order of magnitude than the yields observed previously. Globin expression analysis by high-performance liquid chromatography revealed that these expansion protocols generally yielded red blood cells that expressed a globin profile similar to that expected for the developmental age of the CD34+ cells.
<br/>来源：生物谷
</div>
</div>
</div>
还没有人评论，赶快抢个沙发